Thank you. Henrik, the foundation of Oncopeptides AB is built on our commercial execution in Europe, targeting an estimated 1.5 billion SEK market potential under our current label. In parallel, we are unlocking additional geographic markets through commercial partnerships. Long-term, our PDC platform can unlock multiple indication potential in difficult-to-treat cancers, headlined by our CNS tumor program with initial focus on glioblastoma. Addressing a global market expected to grow to 8 billion USD based on the high unmet need. Our execution during the second quarter has advanced every key pillar of this investment thesis. Commercial momentum delivered 62% revenue growth in Q2 compared to the same period last year. We formally submitted our Type II variation to enter the third-line of multiple myeloma. The glioblastoma window-of-opportunity study was initiated and the first patient was dosed. We expanded our European reach via the Salus distribution partnership in Central and Eastern Europe, while continuing active business development discussions in Japan and other regions. Turning to our commercial performance across Europe, the contribution during the quarter comes from Germany, strong uptake in Italy, and the level-up in Spain.
More than 1,000 patients have now been treated with Pepaxti across Europe since our EMA approval. This growing real-world clinical experience is generating peer-to-peer advocacy and validation. Furthermore, our 1B recommendation in the EMA guidelines continues to play an important role in defining Pepaxti's unique clinical position in a complex treatment landscape. In a rapidly evolving market with many options being launched, it is critical to identify a unique position supported by both real-world data and experience. For Pepaxti, data consistently points to three distinct patient profiles where Pepaxti delivers clear value. First, for patients unable to receive immunotherapy due to, for example, frailty, advanced age, comorbidities, or concerns about the risk for severe infections, Pepaxti serves as an ideal bridge between immune-based therapies. It offers a non-cross-resistant disease control while allowing the immune system and the T cells to recover as an effective post-immunotherapy option. Salvage options for patients who have relapsed or become refractory to almost all other drugs, including BCMA-targeted agents and CAR-T cell therapies. During EHA in Stockholm in June, we hosted a symposium titled "Beyond Immunotherapy," exploring the treatment class of PDC and clinical realities, shared by Professor Maria Krauth and featuring six leading hematologists from Germany, Spain, and Italy; the symposium addressed sequencing strategies and highlighted how Pepaxti's unique PDC mechanism offers an outpatient-friendly solution that does not rely on host immune fitness. I was, of course, attending myself, and I enjoyed meeting and listening to all the experts sharing their views and experience. Seven slightly different perspectives based on the country and the setting they came from, all confirming the unmet need and the use of Pepaxti in the positions in which we believe we can make the most difference for patients. True external validation. In addition to the symposium, we had a Swedish-themed booth. We launched digital engagement campaigns throughout EHA, and we had a high number of qualitative face-to-face interactions with healthcare professionals, mainly from our key markets, but also from other markets across the globe. These activities reinforce our core messaging around the importance for patients to gain access to Pepaxti as they need therapy options, complementing immunotherapy.
Today, we have several collaborations with key experts underway based on the congress activities. In Germany, commercial momentum stepped up during the quarter with steady gains in monthly new patient starts and an expanding prescriber base across university hospitals and office-based practices. We also enrolled the first patient into the prospective MARINA RWE study, strengthening our office-based data generation with strict cost control and volume growth. Germany is progressing towards country-level profitability for the full year. We should be honest and say that it is only the experienced prescribers that use Pepaxti in the exact right position and in fourth-line in Germany. This means that once physicians gain experience, they gain confidence and move from very late lines to the right position. It also means we still have work to do to ensure we get more use in earlier lines, which commonly means even longer treatment duration. In short, there is still a lot of potential to capture in Germany. The German Pepaxti prescriber base continues to demonstrate steady growth with a high number of multiple myeloma prescribers in Germany. We still have many more left to gain. Our focus is naturally unlocking sites with the highest potential.
Italy continues to perform exceptionally well and remains a key growth driver. It represents our most mature market in terms of prescriber experience and fourth-line usage, showing the highest estimated average number of treatment cycles per patient. We are seeing a continuous broadening of the hospital accounts throughout the country. In Spain, we have worked hard to actively manage the local dynamics in a very stressed market. Spain has not only experienced many launches in a very short period, but also unusual limitations in access to HCPs due to the strike that has been ongoing during the full period. We are starting to see the results of our resilience and all our efforts, with a clear step up in commercial uptake and Q2 achieving an all-time high monthly sales level in June. We are continuing to work closely with key opinion leaders, as peer-to-peer recommendations are key in a pressured market to sustain this positive momentum. Our phased rollout across Europe covers an estimated 1.5 billion SEK market potential under the current label, protected by market exclusivity until 2037. We have direct commercial operations established in the phase one and part of our phase two markets. A recent agreement with Salus accelerates entry into Central and Eastern Europe, and I will get back to CEE in a short while. But first, let's focus on a brief update on where we stand with the Type II variation submitted to the EMA.
Our submission to move from fourth-line into third-line treatment represents a transformative opportunity. It can shift our indication from adult patients that are refractory to a proteasome inhibitor, IMiD, and anti-CD38 monoclonal antibody, to patients with at least two prior lines of therapy and who are only refractory to lenalidomide in their last line of therapy. Moving one line up and removing the triple-class refractory requirement allows clinicians to identify and treat patients earlier. Expanding into third-line therapy acts as a commercial and clinical multiplier, coming with the opportunity to double the target patient population in Europe. In addition, the potential to double average treatment duration is based on the phase three OCEAN data. Important to note is that the established German basket model supports innovative pricing and, maybe most important. We do fulfill an unmet need with a mode of action complementary to other therapies. Following our submission between May and July, we expect a CHMP opinion sometime between September and November. In case of a positive opinion, that can lead to an EC decision, which will come plus 30 to 60 days after a potential positive opinion. Timing on the CHMP opinion will depend on the complexity and extent of feedback from the EMA. Should we gain this approval, we will submit reimbursement dossiers in our key markets as soon as administratively possible after the approval. In Germany, a company can, according to local rules, start to sell on a new indication right after the reimbursement dossier has been submitted. In Italy and Spain, a price needs to be concluded for the new indication before off-label sales to third-line patients is possible. We will, of course, keep you updated on the progress. Our partnership strategy allows us to scale globally and capital-efficiently. The agreement, announced during Q2, covers 11 key countries, representing an estimated addressable market with 150 million SEK potential under the current label. Just like we did a launch sequence across Europe, Salus has assessed and made a launch sequence across CEE, where Slovenia was first on that list. It is a small market, but most important from a pricing perspective, to achieve a list price in Slovenia already now in August; this confirms that Salus is a partner with the right competence and drive, and sales in Slovenia can start once a price negotiation is concluded. Regarding the launch sequence in CEE, Croatia and the Czech Republic are next up. In parallel with our current partnerships, we remain very engaged in active partnership discussions in Japan and in other territories. Our pipeline leverages our proprietary PDC and SPiKE platforms. Key assets include OPD5, currently focused on glioblastoma. OPDC3, designed for enhanced selectivity in solid tumors, and OPSP1 are novel natural killer cell engagers. The first major obstacle in brain cancer is crossing the blood-brain barrier. Based on pre-clinical data, we believe we can overcome this barrier. This, however, needs to be confirmed in the clinic, and through our 10-patient window-of-opportunity study at Oslo University Hospital, we are using an approved PDC probe to rapidly demonstrate human brain tumor penetration in a cost-efficient manner, aiming to generate the clinical validation needed for us to take the next step. We enrolled the first patient into the study during Q2. The first step to allow further recruitment of patients was an assessment by the Safety Review Committee. This is completed, and recruitment of additional patients has been initiated. We will keep you posted on the progress. To put our glioblastoma opportunity into perspective, the current standard of care drug, temozolomide, is an alkylating agent. This means alkylators are today considered to be the most effective drug class to use in glioblastoma patients. Glioblastoma is a sturdy and cold tumor, and so far, for example, immunotherapy has been very difficult to get to work. Despite the treatment with temozolomide, the prognosis is poor and the unmet need is high, mainly due to three additional barriers, including poor delivery. Only around 30% of the drug crosses the blood-brain barrier and reaches the brain. It has limited potency. It has relatively low cancer-killing power. This is partly due to the last barrier, which is high and rapid resistance development. The tumor cells quickly adapt and learn to repair the damage that temozolomide causes. In fact, 60% of patients already have a mutation at diagnosis that supports the tumor in its repair process. The treatment targets single-stranded DNA damage within the nucleus. All glioblastoma patients need new treatment options, but these patients do have a high need already in the first line. Our PDCs kill through alkylation, but are engineered to overcome all three challenges; in preclinical testing, they demonstrate 100% blood-brain barrier penetration in vitro and in vivo. Trials demonstrate high glioblastoma cytotoxicity that seems to be independent of the most common mutation for DNA repair. We believe this is due to the high blood-brain barrier penetration in combination with the dual mechanism of action, which damages DNA double strands in the nucleus and in the mitochondria, allowing the PDCs to overcome resistance development. This makes our PDC a uniquely differentiated alkylating drug candidate designed to overcome the most common barriers and treat hard-to-reach aggressive brain tumors where other therapies fall short. If we succeed, we have the opportunity to make a huge difference for patients. Which makes me excited about this program. To summarize, Q2 2026 has been marked by strong execution across all fronts.
We recorded 62% revenue growth in Q2 compared to the same period last year. A strengthened cash position supporting our pathway to 2027. Cash flow positivity. Regulatory submission to the EMA with the purpose to potentially double the number of addressable patients and increase treatment duration. Strategic partnership expansion across 11 key markets and clinical progress in glioblastoma.
Targeting a disease with a very high unmet medical need and a growing global market potential. Thank you for your time and we will now open the line for questions.